As teamLab Planets in Tokyo Welcomes Around 1 Million Visitors From Abroad in a 6-Month Period, the Immersive Museum Unveils the Renewal of Artwork Spaces
31.8.2023 19:00:00 EEST | Business Wire | Press release
teamLab Planets TOKYO DMM ("teamLab Planets"), the body-immersive museum by art collective teamLab in Toyosu, Tokyo, celebrated its fifth anniversary with the renewal of artwork spaces, making it an even more immersive experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830716639/en/
As visitors touch the countless crystals of light floating in the air, the work transforms interactively. On view at teamLab Planets, a body immersive museum in Toyosu, Tokyo. (teamLab, Ephemeral Solidified Light / Photo: teamLab)
In the six months from March to August 2023, the museum has received approximately one million visitors from 182 countries and regions outside of Japan. This makes up 70% of the museum’s total number of visitors (*1). It has also been reported that approximately 1 in 10 visitors to Japan from overseas are visiting teamLab Planets (*2).
NEWLY UNVEILED INSTALLATION: EPHEMERAL SOLIDIFIED LIGHT
Inside an immersive artwork that visitors experience by entering the water, countless masses of light float in the air, each one composed of multiple colors. The boundaries of each color are clearly separated as though they are solid. The seemingly solid color separation of the masses of light is not seen in the natural world, and is caused by extreme synchronization. Through self-organization over time, this synchronization phenomenon creates a large ordered structure.
RENEWAL OF ARTWORK SPACES
In The Infinite Crystal Universe, an artwork that creates a three-dimensional sculpture from a collection of light points, visitors can participate in the work using the teamLab app and create the artwork together with other people in the space. By throwing in a star of your choice from the app, a light sculpture is created in front of you, and the space of this work is created by a group of these light sculptures. With the renewal, five new light sculptures have been added to the installation.
An installation filled with spheres of light that change to ambiguous colors through people’s interactions, Expanding Three-dimensional Existence in Transforming Space, and several other artwork spaces have also been renewed, furthering the experience of physically immersing the entire body.
In addition, teamLab Planets, which was originally scheduled to close at the end of 2023, has been extended to the end of 2027 due to the popularity of the museum.
CONCEPT BEHIND TEAMLAB PLANETS
Together with Others, Immerse your Entire Body, Perceive with your Body, and Become One with the World
teamLab Planets is a museum where you walk through water, and a garden where you become one with the flowers. It comprises 4 large-scale artwork spaces and 2 gardens created by art collective teamLab.
People go barefoot and immerse their entire bodies in the vast artworks together with others. The artworks change under the presence of people, blurring the perception of boundaries between the self and the works. Other people also create change in the artworks, blurring the boundaries between themselves and the works, and creating a continuity between the self, the art, and others.
-----------------------
*1, teamLab Planets Official Website, Ticket Purchasing Data (data obtained from March 1st - Aug 31st, 2023)
*2 “Amazing Nippon / Digital Art Museum in Tokyo Enchants Overseas Tourists - The Japan News” The Japan News by the Yomiuri Shimbun. August 5, 2023.
About the Museum
teamLab Planets TOKYO DMM
6-1-16 Toyosu, Koto-ku, Tokyo
https://www.teamlab.art/e/planets/
Hours
September - November: 09:00 - 22:00
*Last entry 1 hour before closing
*Hours are subject to change. Please check the official website for the latest information.
Closed: September 6th (Wed), October 4th (Wed), November 8th (Wed)
Admission
Adult (18 years and over): 3,800 JPY
Student (13 - 17 years): 2,300 JPY
Child (4 - 12 years): 1,300 JPY
3 years and under: Free
Disability discount: 1,900 JPY
Official Ticket Store
https://teamlabplanets.dmm.com
Food & Shop
Vegan Ramen UZU Tokyo: https://vegan-uzu.com/pages/uzu-tokyo-en
teamLab Flower Shop: https://www.teamlab.art/e/flowershop/
For Media
Press Kit: https://goo.gl/tQXMLm
Highlight Video: https://youtu.be/KAQMAzRjoH0
About PLANETS Co., Ltd.
Established in 2017. Operates and manages the facilities of teamLab Planets TOKYO.
Location: Tokyo Nihonbashi Tower 10F, 2-7-1 Nihonbashi, Chuo-ku, Tokyo
Representative: Takumi Nomoto
About teamLab
teamLab (f. 2001) is an international art collective. Their collaborative practice seeks to navigate the confluence of art, science, technology, and the natural world. Through art, the interdisciplinary group of specialists, including artists, programmers, engineers, CG animators, mathematicians, and architects, aims to explore the relationship between the self and the world, and new forms of perception.
In order to understand the world around them, people separate it into independent entities with perceived boundaries between them. teamLab seeks to transcend these boundaries in our perceptions of the world, of the relationship between the self and the world, and of the continuity of time. Everything exists in a long, fragile yet miraculous, borderless continuity.
teamLab exhibitions have been held in cities worldwide, including New York, London, Paris, Singapore, Silicon Valley, Beijing, and Melbourne among others. teamLab museums and large-scale permanent exhibitions include teamLab Borderless and teamLab Planets in Tokyo, teamLab Borderless Shanghai, teamLab SuperNature Macao, and teamLab Massless Beijing, with more to open in cities including Abu Dhabi, Hamburg, Jeddah, and Utrecht.
teamLab’s works are in the permanent collection of the Museum of Contemporary Art, Los Angeles; Art Gallery of New South Wales, Sydney; Art Gallery of South Australia, Adelaide; Asian Art Museum, San Francisco; Asia Society Museum, New York; Borusan Contemporary Art Collection, Istanbul; National Gallery of Victoria, Melbourne; and Amos Rex, Helsinki, among others.
teamLab is represented by Pace Gallery, Martin Browne Contemporary, and Ikkan Art.
teamLab: https://www.teamlab.art/
Instagram: https://instagram.com/teamlab/
Facebook: https://www.facebook.com/teamLab.inc
Twitter: https://twitter.com/teamLab_net
YouTube: https://www.youtube.com/c/teamLabART
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230830716639/en/
Contact information
PLANETS Co., Ltd. Public Relations Department
E-mail: pr-info@planets.art
Interview: https://forms.gle/fAtnDKLpQKFME6XR9
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom